# MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

> **NCT07144995** · — · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 1143 (estimated)

## Conditions studied

- Advanced Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Fruquintinib
- Ramucirumab

## Interventions

- **DRUG:** Fruquintinib+Paclitaxel
- **DRUG:** Ramucirumab+Paclitaxel

## Key facts

- **NCT ID:** NCT07144995
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2026-08-05
- **Final completion:** 2026-12-31
- **Target enrollment:** 1143 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07144995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07144995, "MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07144995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*